Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Slide: 34 of 46

General Findings of Adverse Event Reports

There are few direct comparisons of DMARDs in children with JIA, and the evidence is insufficient to determine if there are differential rates of adverse effects between drugs or drug classes.

Reported rates of adverse effects are similar between DMARDs and placebo in nearly all published randomized controlled trials. Adverse event rates may be underestimated by clinical trials that exclude patients because of adverse effects in a run-in phase.

The evidence about adverse effects has not been collected or reported systematically in patients with JIA.